Pluri Inc. (PLUR), a biotechnology company specializing in cell-based solutions, announced on Monday that it is assessing its readiness to initiate mass production of PLX-R18, a potential treatment for acute radiation syndrome (H-ARS) following nuclear radiation exposure.
This decision comes in response to increasing global nuclear threats, particularly the ongoing crisis in Ukraine.
PLX-R18 has shown promise in preclinical studies for improving survival and accelerating recovery from H-ARS by stimulating blood cell regeneration.
Pluri is currently evaluating its state-of-the-art manufacturing facility to scale production in the event of heightened demand due to radiological or nuclear emergencies. The U.S. FDA has previously granted Orphan Drug Designation for PLX-R18 and approved its Investigational New Drug application for the treatment of H-ARS.
The company aims to ensure preparedness for any global escalation that could require rapid mass production of PLX-R18.
PLUR closed Friday's trading at $4.90, up 1.03%. In premarket trading today, the stock is up by 3.29% at $5.02.
For comments and feedback contact: editorial@rttnews.com
Business News
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.